HK-listed Luye Pharma may secure up to $220m from China's state-owned fund manager

HK-listed Luye Pharma may secure up to $220m from China's state-owned fund manager

Photo by Raimond Klavins on Unsplash

23 July, 2024

Edited by: Padma Priya

Shenzhen Investment Holdings Capital

Printed by Unregistered user on Sun, 20 Jul 2025 10:29:23 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Nippon Steel to dissolve JV with China's Baoshan after 20 years

Venture Capital

Xellar Biosystems raises angel+ round and 40 other Greater China deals worth over $431m

Read more from Greater China

Venture Capital

China’s CAS Star hits first close of new hard tech fund

China’s Unitree Robotics starts IPO process